Patient-Derived Head and Neck Cancer Organoids Allow Treatment Stratification and Serve as a Tool for Biomarker Validation and Identification

Organoids were established from head and neck cancer (HNC) patient tumor tissue and characterized using immunohistochemistry and DNA sequencing. Organoids were exposed to chemo- and radiotherapy and a panel of targeted agents, and organoid response was correlated with patient clinical response.